Skip to main content

Table 3 Demographics and clinical characteristics of the patient cohort from whom rare NTM were isolated

From: Frequency and clinical implications of the isolation of rare nontuberculous mycobacteria

Demographics

N (%)

   Age (year), median (range)

68.0 (30.0–84.0)

   Sex (Male)

39/68 (57.4)

   Body Mass Index (kg/m2), median (range)

22.4 (15.9–29.0)

Habitual factors

N (%)

   Smoking

19/68 (33.8)

     Ex-smoker

13/68 (22.4)

     Current smoker

6/68 (10.3)

Past medical history

N (%)

   Previous history of TB

24/68 (35.3)

   Sinusitis

9/68 (13.2)

   Measles

3/68 (4.4)

   Pertussis

1/68 (1.5)

Comorbidities

N (%)

   Malignancies

7/68 (10.3)

     Lung cancer

1/68 (1.5)

   Diabetes

6/68 (8.8)

   Cerebrovascular disease

2/68 (2.9)

   Rheumatoid arthritis

3/68 (4.4)

   Inflammatory bowel disease

0/68 (−)

   Gastroesophageal reflux

0/68 (−)

   Underlying lung disease

 

     COPD

4/68 (5.9)

     Asthma

4/68 (5.9)

     TB-destroyed lung

3/68 (4.4)

     Interstitial lung disease

1/68 (1.5)

     Bronchiectasis

23/68 (33.8)

   HIV infection

1/68 (1.5)

   Post-transplantation status

0/68 (−)

Symptoms

N (%)

   Cough

30/68 (44.1)

   Dyspnea

13/68 (19.1)

   Hemoptysis

11/68 (16.2)

   Sputum

39/68 (57.4)

   Fever

6/68 (8.8)

   Myalgia

4/68 (5.9)

   Weight loss

6/68 (8.8)

Physical examination

N (%)

   Postnasal drip

10/68 (14.7)

   Crackle

4/68 (5.8)

   Wheezing

1/68 (1.5)

   Murmur

0/68 (−)

   Clubbing

0/68 (−)

   Peripheral edema

0/68 (−)

Drug use

 

   TNF-alpha inhibitor*

1/68 (1.5)

   Steroid (5–10 mg daily)*

3/68 (4.4)

   Other immunomodulatory drugs*

2/68 (2.9)

  1. *All these drugs were used for the treatment of patients with rheumatoid arthritis.